The latest Investing Matters Podcast episode featuring Jeremy Skillington, CEO of Poolbeg Pharma has just been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

GlaxoSmithKline Sees 2% Forex Revenue Gain In Fourth Quarter

Fri, 11th Jan 2019 13:42

LONDON (Alliance News) - GlaxoSmithKline PLC on Friday said currency movements will positively impact fourth quarter performance but will dent 2018 revenue and adjusted earnings per share.

In a pre-quarterly results communication document, Glaxo said average exchange rates in the fourth quarter of 2018, per pound sterling, stood at USD1.27, EUR1.13, and JPY144.

Based on the average exchange rate, the FSTE100 listed pharma company is predicting a foreign exchange boost of 2% to fourth quarter sales.

The company, however, expects currency movements to provide greater boost to fourth quarter adjusted earnings per share than to sales due to "the mix of currency movements relative to the mix of costs". Glaxo did not provide a percentage impact on fourth quarter adjusted earnings per share.

In the first three quarters of 2018, however, Glaxo recorded a 4% negative impact from foreign exchange movements.

Foreign exchange rates is expected to have an overall 3% detrimental effect on sales, the company said. As with the fourth quarter, the negative impact of foreign exchange on adjusted earnings per share for 2018 as a whole is likely to be worse than its effect on sales.

Average rates for 2018 for the company stood at GBP1.33, EUR1.13, and JPY147 per pound sterling.

Glaxo will release its fourth quarter results on February 6. Shares in the company were down 0.9% at 1,522.40 pence on Friday.

Related Shares

More News
25 Apr 2024 15:53

GlaxoSmithKline sues Pfizer and BioNTech over Covid-19 vaccine technology

April 25 (Reuters) - GlaxoSmithKline sued Pfizer and BioNTech in Delaware federal court on Thursday, accusing them of infringing GSK patents related...

24 Apr 2024 14:19

UK earnings, trading statements calendar - next 7 days

24 Apr 2024 09:21

GSK's endometrial cancer drug receives FDA approval

(Sharecast News) - Drugmaker GSK said on Wednesday that the US Food and Drug Administration has accepted a supplemental Biologics License Application ...

24 Apr 2024 09:14

GSK's Jemperli with chemotherapy accepted for priority review by FDA

(Alliance News) - GSK PLC on Wednesday said that the US Food & Drug Administration has accepted a supplemental biologics licence application for Jempe...

17 Apr 2024 08:46

TOP NEWS: GSK hails data on Shingles vaccine and gonorrhoea treatment

(Alliance News) - GSK PLC on Wednesday reported new test data for its shingles vaccine and for a potential new oral treatment for a form of gonorrhoea...

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.